Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization

Mohammad Ali Sadiq, Mostafa Hanout, Salman Sarwar, Muhammad Hassan, Aniruddha Agarwal, Yasir Jamal Sepah, Diana V. Do, Quan Dong Nguyen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.

Original languageEnglish (US)
Pages (from-to)310-316
Number of pages7
JournalDevelopments in Ophthalmology
Volume55
DOIs
StatePublished - Jan 1 2015

Fingerprint

Growth Inhibitors
Platelet-Derived Growth Factor
Vascular Diseases
Macular Degeneration
Degenerative Myopia
Retinal Vein Occlusion
Retinopathy of Prematurity
Diabetic Retinopathy
Blindness
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Sadiq, M. A., Hanout, M., Sarwar, S., Hassan, M., Agarwal, A., Sepah, Y. J., ... Nguyen, Q. D. (2015). Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization. Developments in Ophthalmology, 55, 310-316. https://doi.org/10.1159/000438953

Platelet-derived growth factor inhibitors : A potential therapeutic approach for ocular neovascularization. / Sadiq, Mohammad Ali; Hanout, Mostafa; Sarwar, Salman; Hassan, Muhammad; Agarwal, Aniruddha; Sepah, Yasir Jamal; Do, Diana V.; Nguyen, Quan Dong.

In: Developments in Ophthalmology, Vol. 55, 01.01.2015, p. 310-316.

Research output: Contribution to journalArticle

Sadiq, MA, Hanout, M, Sarwar, S, Hassan, M, Agarwal, A, Sepah, YJ, Do, DV & Nguyen, QD 2015, 'Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization', Developments in Ophthalmology, vol. 55, pp. 310-316. https://doi.org/10.1159/000438953
Sadiq, Mohammad Ali ; Hanout, Mostafa ; Sarwar, Salman ; Hassan, Muhammad ; Agarwal, Aniruddha ; Sepah, Yasir Jamal ; Do, Diana V. ; Nguyen, Quan Dong. / Platelet-derived growth factor inhibitors : A potential therapeutic approach for ocular neovascularization. In: Developments in Ophthalmology. 2015 ; Vol. 55. pp. 310-316.
@article{36f66890165e4a54879952b1b6a1ea0d,
title = "Platelet-derived growth factor inhibitors: A potential therapeutic approach for ocular neovascularization",
abstract = "Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.",
author = "Sadiq, {Mohammad Ali} and Mostafa Hanout and Salman Sarwar and Muhammad Hassan and Aniruddha Agarwal and Sepah, {Yasir Jamal} and Do, {Diana V.} and Nguyen, {Quan Dong}",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000438953",
language = "English (US)",
volume = "55",
pages = "310--316",
journal = "Developments in Ophthalmology",
issn = "0250-3751",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Platelet-derived growth factor inhibitors

T2 - A potential therapeutic approach for ocular neovascularization

AU - Sadiq, Mohammad Ali

AU - Hanout, Mostafa

AU - Sarwar, Salman

AU - Hassan, Muhammad

AU - Agarwal, Aniruddha

AU - Sepah, Yasir Jamal

AU - Do, Diana V.

AU - Nguyen, Quan Dong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.

AB - Retinochoroidal vascular diseases are the leading causes of blindness in the developed world. They include diabetic retinopathy, retinal vein occlusion, retinopathy of prematurity, age-related macular degeneration (AMD), and pathological myopia, among many others. Several different therapies are currently under consideration for the aforementioned disorders. In the following section, agents targeting platelet-derived growth factors (PDGF) are discussed as a potential therapeutic option for retinochoroidal vascular diseases. PDGF play an important role in the angiogenesis cascade that is activated in retinochoroidal vascular diseases. The mechanism of action, side effects, efficacy, and the potential synergistic role of these agents in combination with other treatment options is discussed. The future of treatment of retinochoroidal vascular diseases, particularly neovascular AMD, has become more exciting due to agents like PDGF antagonists.

UR - http://www.scopus.com/inward/record.url?scp=84947267492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947267492&partnerID=8YFLogxK

U2 - 10.1159/000438953

DO - 10.1159/000438953

M3 - Article

C2 - 26501397

AN - SCOPUS:84947267492

VL - 55

SP - 310

EP - 316

JO - Developments in Ophthalmology

JF - Developments in Ophthalmology

SN - 0250-3751

ER -